Moreover, the sorafenib resistant tumour cells regained sensitivity by the combined treatment of sorafenib with EZH2 intervention, which might be helpful for the better understanding of the molecule mechanism of thyroid cancer tumorigenesis and for investigating suitable novel target for thyroid carcinoma therapy. Here, EZH2 is linked to neoplasm.